Free Trial

Carisma Therapeutics (CARM) News Today

Carisma Therapeutics logo
$1.00
+0.03 (+3.09%)
(As of 11/1/2024 ET)
Leadership Transition at Carisma Therapeutics’ Board of Directors
Carisma Therapeutics, Inc. stock logo
HC Wainwright Reaffirms "Buy" Rating for Carisma Therapeutics (NASDAQ:CARM)
HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of Carisma Therapeutics in a research note on Wednesday.
Carisma Therapeutics, Inc. stock logo
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update
Carisma Therapeutics, Inc. (NASDAQ:CARM - Get Free Report) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 1,570,000 shares, a decrease of 13.7% from the April 30th total of 1,820,000 shares. Currently, 7.8% of the company's stock are short sold. Based on an average daily trading volume, of 174,500 shares, the days-to-cover ratio is currently 9.0 days.
The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
Carisma Therapeutics, Inc. stock logo
HC Wainwright Trims Carisma Therapeutics (NASDAQ:CARM) Target Price to $8.00
HC Wainwright dropped their price objective on shares of Carisma Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday.
Carisma Therapeutics, Inc. stock logo
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of "Buy" from Analysts
Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM - Get Free Report) have been assigned an average rating of "Buy" from the five research firms that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month target price
Carisma Therapeutics, Inc. stock logo
Carisma Therapeutics (NASDAQ:CARM) Research Coverage Started at BTIG Research
BTIG Research initiated coverage on shares of Carisma Therapeutics in a research report on Thursday. They set a "buy" rating and a $6.00 price objective on the stock.
Carisma Therapeutics, Inc. stock logo
Q1 2024 Earnings Estimate for Carisma Therapeutics, Inc. Issued By Capital One Financial (NASDAQ:CARM)
Carisma Therapeutics, Inc. (NASDAQ:CARM - Free Report) - Analysts at Capital One Financial lifted their Q1 2024 earnings estimates for shares of Carisma Therapeutics in a research report issued on Tuesday, April 2nd. Capital One Financial analyst N. Quibria now expects that the company will post
Get Carisma Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.

625,000% Gain (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

CARM Media Mentions By Week

CARM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CARM
News Sentiment

0.50

0.43

Average
Medical
News Sentiment

CARM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CARM Articles
This Week

5

1

CARM Articles
Average Week

Get Carisma Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CARM) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners